68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .
Outcomes of pharmacist-managed diabetes care services in a community health center.
PURPOSE The outcomes of pharmacist-managed diabetes care services in a community health center were studied . METHODS Eligible patients were over age 18 years and had a diagnosis of type 2 diabetes mellitus . Patients were r and omly assigned by the clinical pharmacist and nurse to the intervention group ( n = 76 ) or control group ( n = 73 ) . Patients in the intervention group were enrolled in a pharmacist-managed diabetes care program . Patients in the control group received the st and ard diabetes care . The primary endpoint was reduction in glycosylated hemoglobin ( HbA(1c ) ) ; secondary outcome measures included weight loss , an improved body mass index , decreased blood pressure , and an improved lipid panel . Quality -of-life measures ( health level , satisfaction , impact , worry about disease , and worry about social and vocational issues ) were also assessed . RESULTS Demographic differences between groups were not remarkable . Mean HbA(1c ) levels fell significantly ( p < 0.05 ) from baseline to nine months in both groups . A difference of 1.0 was reported between the groups ' HbA(1c ) levels ( 95 % confidence interval , 0.08 - 1.78 ; p < 0.05 ) . Satisfaction level improved from 63.7 to 77.4 in the intervention group , which was significant when compared with the control group , whose satisfaction score improved from 57.0 to 63.4 ( p < 0.05 ) . CONCLUSION Patients with type 2 diabetes mellitus who received pharmacist-managed diabetes care  demonstrated improved HbA(1c ) , systolic blood pressure , and low-density-lipoprotein cholesterol levels and quality -of-life measures and met treatment goals more often than patients receiving st and ard care
68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .